Paolo Calabrò: Lower LDL-C Variability With PCSK9 Inhibitors and Inclisira
Paolo Calabrò, Director of the Cardiovascular Department at S. Anna and S. Sebastiano Hospital, shared on LinkedIn:
”Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy.”
Title: Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Authors: Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Andrea Zito, Gennaro Porcelli, Domenico Panico, Giovanni Argenziano, Demetrio Iaria, Maria Grazia Monaco, Vincenzo De Sio, Felice Gragnano, Michele Golino, Massimiliano Ruscica, Stefano Carugo, Alberto Corsini, Paolo Calabrò
Read the full article here.
Stay updated with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin